共查询到20条相似文献,搜索用时 31 毫秒
1.
5-Fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer 总被引:3,自引:0,他引:3
David?P.?Eisenberg Prasad?S.?Adusumilli Karen?J.?Hendershott Zhenkun?Yu Michael?Mullerad Mei-Ki?Chan Ting-Chao?Chou Yuman?Fong
Oncolytic herpes viruses are attenuated, replication-competent viruses that selectively infect, replicate within, and lyse
cancer cells and are highly efficacious in the treatment of a wide variety of experimental cancers. The current study seeks
to define the pharmacologic interactions between chemotherapeutic drugs and the oncolytic herpes viral strain NV1066 in the
treatment of pancreatic cancer cell lines. The human pancreatic cancer cell lines Hs 700T, PANC-1, and MIA PaCa-2 were treated in vitro with NV1066 at multiplicities of infection (MOI; ratio of the number of viral particles per tumor
cell) ranging from 0.01 to 1.0 with or without 5-fluorouracil (5-FU) or gemcitabine. Synergistic efficacy was determined by
the isobologram and combination-index methods of Chou and Talalay. Viral replication was measured using a standard plaque
assay. Six days after combination therapy, 76% of Hs 700T cells were killed compared with 43% with NV1066 infection alone
(MOI = 0.1) or 0% with 5-FU alone (2 βmol/L) (P < .01). Isobologram and combination-index analyses confirmed a strongly synergistic
pharmacologic interaction between the agents at all viral and drug combinations tested (LD5 to LD95) in the three cell lines.
Dose reductions up to 6- and 78-fold may be achieved with combination therapy for NV1066 and 5-FU, respectively, without compromising
cell kill. 5-FU increased viral replication up to 19-fold compared with cells treated with virus alone. Similar results were
observed by combining gemcitabine and NV1066. We have demonstrated that 5-FU and gemcitabine potentiate oncolytic herpes viral
replication and cytotoxicity across a range of clinically achievable doses in the treatment of human pancreatic cancer cell
lines. The potential clinical implications of this synergistic interaction include improvements in efficacy, treatment-associated
toxicity, tolerability of therapeutic regimens, and quality of life. These data provide the cellular basis for the clinical
investigation of combined oncolytic herpes virus therapy and chemotherapy in the treatment of pancreatic cancer.
Presented at the Forty-Sixth Annual Meeting of The Society for Surgery of the Alimentary Tract, Chicago, Illinois, May 141-18,
2005 (oral presentation).
Supported in part by training grant T 32 CA09501 (D.P.E. and K.J.H.), AACR-AstraZeneca Cancer Research and Prevention fellowship
(P.S.A), grants RO1 CA 76416 and RO1 CA/DK80982 (Y.F.) from the National Institutes of Health, grant BC024118 from the U.S.
Army (Y.F.), grant IMG0402501 from the Susan G. Komen Foundation (Y.F.), and grant 032047 from Flight Attendant Medical Research
Institute (Y.F.). 相似文献
2.
Tae-Jin Song M.D. Ph.D. David P. Eisenberg M.D. Prasad S. Adusumilli M.D. Michael Hezel B.S. Yuman Fong M.D. 《Journal of gastrointestinal surgery》2006,10(4):532-542
The rising incidence of hepatocellular carcinoma (HCC) in western countries, along with the poor prognosis offered by present-day
treatment modalities, makes novel therapies for this disease necessary. Oncolytic herpes simplex viruses (HSV) are replication-competent
viruses that are highly effective in the treatment of a wide variety of experimental models of human malignancies. This study
seeks to investigate the effectiveness of oncolytic herpes viruses in the treatment of primary HCC cell lines. Sixteen commercially
available human HCC cell lines were studied. G207 is an attenuated, replication-competent, oncolytic HSV engineered to selectively
replicate within cancer cells. Cell lines were tested for viral sensitivity to G207 and their ability to support viral replication
using standard cytotoxicity and viral replication assays. Eleven of 16 cell lines were moderately to highly sensitive to G207
viral oncolysis. HCC cell lines additionally demonstrated the ability to support viral replication in vitro with as high as
800-fold amplification of the administered viral dose observed. G207 is cytotoxic to, and efficiently replicates within, HCC
cell lines in vitro. From these data, we suggest that oncolytic HSV therapy may have a role in the treatment of HCC, and in
vivo studies are warranted.
Presented in part at the 2005 American Hepato-Pancreato-Biliary Association Congress, Hollywood, Florida, April 14–17, 2005.
Supported by grants R01CA75461 and R01CA72632 from the National Institutes of Health, and by grant MBC-99366 from the American
Cancer Society (Yuman Fong). 相似文献
3.
Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases 总被引:1,自引:0,他引:1
下载免费PDF全文
![点击此处可从《Annals of surgery》网站下载免费的PDF全文](/ch/ext_images/free.gif)
OBJECTIVE: To determine the effects of hypoxia-induced ribonucleotide reductase (RR) production on herpes oncolytic viral therapy. SUMMARY BACKGROUND DATA: Hypoxia is a common tumor condition correlated with therapeutic resistance and metastases. Attenuated viruses offer a unique cancer treatment by specifically infecting and lysing tumor cells. G207 is an oncolytic herpes virus deficient in RR, a rate-limiting enzyme for viral replication. METHODS: A multimerized hypoxia-responsive enhancer was constructed (10xHRE) and functionally tested by luciferase assay. 10xHRE was cloned upstream of UL39, the gene encoding the large subunit of RR (10xHRE-UL39). CT26 murine colorectal cancer cells were transfected with 10xHRE-UL39, incubated in hypoxia (1% O2) or normoxia (21% O2), and infected with G207 for cytotoxicity assays. CT26 liver metastases, with or without 10xHRE-UL39, were created in syngeneic Balb/C mice (n = 40). Livers were treated with G207 or saline. Tumors were assessed and stained immunohistochemically for G207. RESULTS: 10xHRE increased luciferase expression 33-fold in hypoxia versus controls (P < 0.001). In normoxia, 10xHRE-UL39 transfection did not improve G207 cytotoxicity. In hypoxia, G207 cytotoxicity increased 87% with 10xHRE-UL39 transfection versus nontransfected cells (P < 0.001). CT26 were resistant to G207 alone. Combining 10xHRE-UL39 with G207 resulted in a 66% decrease in tumor weights (P < 0.0001) and a 65% reduction in tumor nodules (P < 0.0001) versus G207 monotherapy. 10xHRE-UL39-transfected tumors demonstrated greater viral staining. CONCLUSIONS: Hypoxia-driven RR production significantly enhances viral cytotoxicity in vitro and reduces tumor burden in vivo. G207 combined with RR under hypoxic control is a promising treatment for colorectal cancer, which would otherwise be resistant to oncolytic herpes virus alone. 相似文献
4.
5.
Prasad?S.?Adusumilli David?P.?Eisenberg Yun?Shin?Chun Keun-Won?Ryu Leah?Ben-?Porat Karen?J.?Hendershott Mei-Ki?Chan Rumana?Huq Christopher?C.?Riedl Yuman?Fong
Completeness of cytoreduction is an independent prognostic factor after cure-intended surgery for peritoneal carcinomatosis.
NV1066, a genetically engineered herpes simplex virus carrying the transgene for green fluorescent protein, selectively infects
cancer cells. We sought to determine the feasibility of virally directed fluorescent imaging in the intraoperative detection
of minimal residual disease after cytoreductive surgery. NV1066 infected human gastric cancer cells, OCUM-2MD3, and mesothelioma
JMN cells at all doses. The infected cells expressed green fluorescent protein and were killed. OCUM-2MD3, and mesothelioma
JMN cells at all doses. Peritoneal carcinomatosis was established in mice by injection of OCUM cells into the peritoneal cavity.
Forty-eight hours after intraperitoneal injection of NV1066, two experienced surgeons resected all visible disease and identified
mice free of disease. Eight of 13 mice thought to be free of disease were found to have residual disease as identified by
green fluorescence (mean number of observations: 5; range: 1–9). Residual disease was most frequently observed in the retroperitoneum,
pelvis, peritoneal surface, and liver. Specificity of NV1066 infection to tumor nodules was confirmed by immunohistochemistry
and by polymerase chain reaction for viral gene. Virally directed fluorescent imaging, a novel molecular imaging technology,
can be used for real-time visualization of minimal residual disease after cytoreductive surgery and can improve the completeness
of cure-intended resection.
Presented at the Forty-Sixth Annual Meeting of The Society for Surgery of the Alimentary Tract, Chicago, Illinois, May 14–18,
2005 (oral presentation)
Supported in part by AstraZeneca Cancer Research and Prevention fellowship (P.S.A), training grant T 32 CA09501 (D.P.E and
K.J.H.), grants RO1 CA 76416 and RO1 CA/DK80982 (Y.F.) from the National Institutes of Health, grant BC024118 from the U.S.
Army (Y.F.), grant IMG0402501 from the Susan G. Komen Foundation (Y.F. and P.S.A), and grant 032047 from the Flight Attendant
Medical Research Institute (Y.F. and P.S.A). 相似文献
6.
Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma 总被引:2,自引:0,他引:2
Richard H. Pin Maura Reinblatt William J. Bowers Howard J. Federoff Yuman Fong 《Journal of gastrointestinal surgery》2004,8(7):812-823
Tumor hypoxia induces vascular endothelial growth factor (VEGF) expression, which stimulates tumor angiogenesis. The VEGF
pathway is inhibited by soluble VEGF receptors (soluble fetal liver kinase-1 [sFlk-1]) that bind VEGF and block its interaction
with endothelial cells. Herpes simplex virus (HSV)-derived amplicons are replication-incompetent viruses used for gene delivery.
We attempt to attenuate angiogenesis and inhibit hepatoma growth through amplicon-mediated expression of sFlk-1 under hypoxic
control. A multimerized hypoxia-responsive enhancer (10xHRE) was cloned upstream of the sFlk-1 gene (10xHRE/sFlk-1). An amplicon
expressing 10xHRE/sFlk-1 was genetically engineered (HSV10xHRE/sFlk-1). SK-HEP-1 human hepatoma cells were transduced with
HSV10xHRE/sFlk-1 and incubated in normoxia (21% O2) or hypoxia (1% O2). Human umbilical vein endothelial cell assay evaluated capillary inhibition. Western blot assessed sFlk-1 expression. SK-HEP-1
flank tumors (n = 24) in athymic mice were treated with HSV10xHRE/sFlk-1. Media from hypoxic SK-HEP-1 transduced with HSV10xHRE/sFlk-1
yielded an 80% reduction in capillary formation (P < 0.005), whereas normoxic SK-HEP-1 yielded a 25% reduction (P < 0.05). Western blot of SK-HEP-1 transduced with HSV10xHRE/sFlk-1 demonstrated greater sFlk-1 expression in hypoxia vs.
normoxia. SK-HEP-1 tumors treated with HSV10xHRE/sFlk-1 yielded a 72% reduction in volume vs. the control group (P < 0.000001). HSV amplicon-mediated delivery of a hypoxia-inducible soluble VEGF receptor substantially reduces new vessel
formation and tumor growth in hepatoma.
Presented at the Forty-Fifth Annual Meeting of the Society for Surgery of the Alimentary Tract, New Orleans, Louisiana, May
15–19, 2004 (oral presentation).
Supported in part by grants RO1 CA 76416 and RO1 CA/DK80982 (Y.F.) from the National Institutes of Health, grant MBC-99366
(Y.F.) from the American Cancer Society, and grant BC024118 from the US Army and Rochester Nathan Shock Center. 相似文献
7.
Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses 总被引:5,自引:1,他引:4
Priscilla F. McAuliffe M.D. William R. Jarnagin M.D. Paul Johnson Ph.D. Keith A. Delman M.D. Howard Federoff M.D. Ph.D. Yuman Fmg M.D. 《Journal of gastrointestinal surgery》2000,4(6):580-588
Pancreatic cancer is an aggressive, rapidly fatal disease against which current nonsurgical therapy has minimal impact. This
study evaluates the efficacy of two novel, replication-competent, multimutated herpes viruses (G207 and NV1020) in an experimental
model of pancreatic cancer. Four human pancreatic carcinoma cell lines were exposed to G207 or NV1020, and cell survival and
viral progeny production were determined. Flank tumors in athymic mice were subjected to single or multiple injections of
1 X 107 G207 or NV1020, and tumor volume was evaluated over time. For all of the cell lines, G207 and NV1020 produced infection,
viral replication, and cell lysis (P <0.05). NV1020 resulted in a higher production of viral progeny compared to G207. The
efficacy of viral tumor cell kill was greatest in those cells with the shortest in vitro doubling time. For flank tumors derived
from hs766t, single or multiple injections of both viruses were equally effective and significantly reduced flank tumor burden
(P <0.05). Complete hs766t flank tumor eradication was achieved in 25% (5 of 20) of animals treated with G207 and 40% (8 of
20) of animals treated with NV1020. In vivo efficacy correlated with in vivo tumor doubling time. There were no adverse effects
related to viral administration observed in any animal. NV1020 and G2O7 effectively infect and kill human pancreatic cancer
cells in vitro and in vivo. Given the lack of effective nonoperative treatments for pancreatic cancer, oncolytic herpes viruses
should be considered for clinical evaluation.
Presented in part at the Forty-First Annual Meeting of The Society for Surgery of the Alimentary Tract, San Diego, Calif.,
May 21–24, 2000. 相似文献
8.
Saiko Sugiura Fumi Goshima Hiroki Takakuwa Tetsutaro Sata Tsutomu Nakashima Yukihiro Nishiyama 《Otolaryngology--head and neck surgery》2004,130(4):470-478
OBJECTIVE: Attenuated, replication-competent herpes simplex viruses (HSVs) have shown promise as antitumor agents for cancer therapy. In this study, we sought to develop a novel type of oncolytic HSV with more potent antitumor activity for use in localized malignant tumors. STUDY DESIGN: A new, attenuated multimutated HSV (termed HL) was developed, and then a highly metastatic murine fibrosarcoma cell line, NfSa Y83, was injected into the necks or flanks of immunocompetent C3H mice. The mice were treated with attenuated HSV mutants by intratumoral injection, and antitumor efficacy was assessed by measuring tumor dimensions and overall survival rates. RESULTS: Treatment with intratumoral injection of HL resulted in marked regression of tumors. In fact, roughly 75% of flank tumors and 50% of neck tumors were completely eradicated. CONCLUSION: A novel type of attenuated HSV recombinant HL demonstrated a remarkable antitumor efficacy in a localized tumor model in mice. 相似文献
9.
10.
Viral oncolysis represents a unique strategy to exploit the natural process of viral replication to kill tumor cells. Although this concept dates back nearly a century, recent advances in the fields of molecular biology and virology have enabled investigators to genetically engineer viruses with greater potency and tumor specificity. In this article we review the general mechanisms by which oncolytic viruses achieve their antineoplastic efficacy and specificity. We focus on the development of several classes of oncolytic viruses for the treatment of malignant liver tumors, including adenoviruses, vaccinia viruses, and herpes simplex viruses, and discuss the results of clinical trials for these viruses. We also describe results from our laboratory research program, which is focused on developing effective, liver tumor–specific Herpes simplex virus 1 mutants. 相似文献
11.
Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer 总被引:4,自引:0,他引:4
Bennett JJ Malhotra S Wong RJ Delman K Zager J St-Louis M Johnson P Fong Y 《Annals of surgery》2001,233(6):819-826
OBJECTIVE: To assess the strategy of combining oncolytic herpes simplex virus (HSV) therapy with immunomodulatory therapy as treatment for experimental colon cancer. The oncolytic HSV recombinant NV1023 and the interleukin 12 (IL-12)-secreting oncolytic NV1042 virus were evaluated in vitro and in vivo with respect to antitumor efficacy. SUMMARY BACKGROUND DATA: Genetically engineered, replication-conditional, attenuated HSVs have shown oncolytic activity against a wide variety of solid malignancies. Other strategies for treating cancer have involved immunomodulation and cytokine gene transfer using viral vectors. This study has combined both of these strategies by inserting the murine IL-12 gene into a replication-competent HSV. This approach allows oncolytic therapy to replicate selectively within and lyse tumor cells while providing the host immune system with the cytokine stimulus necessary to recruit and activate inflammatory cells needed to enhance the antitumor effect. METHODS: NV1023 is a multimutant HSV based on the wild-type HSV-1 F strain. NV1042 was created by insertion of the mIL-12 gene into NV1023. Cytotoxicity and viral proliferation of both NV1023 and NV1042 within murine CT26 colorectal cancer cells were first shown. Cells infected with NV1042 were then shown to produce significant levels of IL-12. Using an experimental flank model of colon cancer, mice were treated with both high and low doses of NV1023 or NV1042 and were followed up for both cure and reduction in tumor burden. RESULTS: Both viruses could replicate within and kill CT26 cells in vitro, with 100% cytotoxicity achieved after infection by either virus. Only NV1042 could produce mIL-12. Therapy using high viral doses to treat animals in vivo showed equal efficacy between NV1023 and NV1042, with five of seven cures for each virus. When viral doses were lowered, only the cytokine-producing NV1042 virus could reduce tumor burden and cure animals of their disease. CONCLUSIONS: Both NV1023 and NV1042 have the oncolytic potential to kill colon cancer cells at higher doses. Cytokine production by NV1042 may allow lower doses of viral therapy to be used without losing antitumor efficacy. The combination of oncolytic viral therapy and immunomodulatory strategies should be further investigated as treatment for colon cancer. 相似文献
12.
The use of replication-competent viruses that can selectively replicate in and destroy neoplastic cells is an attractive strategy for treating cancer. Various oncolytic viruses have been taken to clinical trials since a recombinant virus was first applied to cancer patients a decade ago. The concept of the therapy is simple: infectious virus kills the host cancer cells in the course of viral replication. It is important, however, that the virus does not harm the surrounding normal tissue. Oncolytic viruses can be classified largely into two groups: DNA viruses genetically engineered to achieve cancer specificity (e.g. adenovirus, herpes simplex virus and vaccinia) and RNA viruses of which human is not the natural host (e.g. Newcastle disease virus and reovirus). Prostate cancer has always been one of the major targets of oncolytic virus therapy development. The result of six clinical trials for prostate cancer has been published and several trials are now going on. Forty-eight of 83 (58%) patients evaluated in the phase I studies demonstrated a >25% decrease in serum prostate-specific antigen level without evidence of severe toxicities. The result shows the oncolytic virus therapy is promising toward clinical application. Here, we review the recent advances in the field and summarize the results from clinical trials. 相似文献
13.
14.
Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer 总被引:5,自引:1,他引:5
Sarah A. Little M.D. William R. Jarnagin M.D. Ronald P. DeMatteo M.D. Leslie H. Blumgart M.D. Yuman Fong M.D. 《Journal of gastrointestinal surgery》2002,6(1):88-94
Diabetes is associated with alterations in liver metabolism and immune response that may influence post-operative recovery
and long-term survival after hepatectomy for cancer. Patients with type I or type II diabetes mellitus submitted to a potentially
curative hepatic resection for metastatic colorectal cancer were identified from the prospective database, and compared with
patients with hepatic colorectal metastases submitted to resection during the same time interval, but without diabetes mellitus.
Data on operative morbidity and mortality and long-term survival were analyzed. Between December 1990 and July 1999, a total
of 727 patients underwent hepatic resection, 61 of whom (8.1%) had type I and type II diabetes mellitus. Operative mortality
in the diabetic patients was significantly greater than in nondiabetic patients (8% vs. 2%, P < 0.02). Among patients with diabetes mellitus, four of the five perioperative deaths were due to liver failure after major
hepatic resection (lobectomy or greater). All four of these patients had significant parenchymal abnormality (three with steatosis).
Long-term survival was identical to that in nondiabetic control subjects. We conclude that the presence of diabetes is associated
with a higher incidence of perioperative mortality. In patients with diabetes mellitus and parenchymal steatosis, major hepatic
resection should be undertaken with caution.
Supported in part by grants RO1 CA 75416, RO1 CA 72632, and RO1 CA 61524 (Y.F.) from the National Institutes of Health, grant
MBC-99366 (Y.F.) from the American Cancer Society, and the St. Andrews Society of New York (S.A.L.). 相似文献
15.
BACKGROUND: Although conventional radiation therapy and surgery are potentially curative treatments for organ-confined prostate cancer, there are few effective treatments for metastatic disease. Oncolytic viruses have shown considerable promise for the treatment of solid tumors including prostate cancer. We recently demonstrated that incorporation of a cell membrane fusion capability into an oncolytic herpes simplex virus (HSV) can significantly increase the antitumor potency of the virus. METHODS: We used a mouse model of primary and metastatic human prostate cancer established from PC-3M-Pro4 to evaluate three different types of oncolytic HSVs: non-fusogenic Baco-1, singly fusogenic Synco-2, and doubly fusogenic Synco-2D. RESULTS: Our results show that Synco-2D has greater oncolytic activity than either Baco-1 or Synco-2 virus. Against lung metastases of human prostate cancer xenografts, intravenous administration of Synco-2D had produced a significant reduction of tumor nodules by day 40 post-inoculation as compared with Synco-2 (P < 0.05), Baco-1 (P < 0.01), and PBS control (P < 0.01). CONCLUSIONS: We conclude that the doubly fusogenic Synco-2D is an effective therapeutic agent for human metastatic prostate cancer. 相似文献
16.
Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast Cancer 总被引:1,自引:0,他引:1
Kimata H Imai T Kikumori T Teshigahara O Nagasaka T Goshima F Nishiyama Y Nakao A 《Annals of surgical oncology》2006,13(8):1078-1084
Background An oncolytic herpes simplex virus type 1 mutant (HF10) has been isolated and evaluated for antitumor efficacy in a syngeneic
immunocompetent mouse model, where it was effective against cancer and conferred resistance to rechallenge with tumor cells
in all surviving mice. Several studies have shown that HF10 is effective and safe for use against localized or peritoneally
disseminated nonneuronal malignant tumors in animals.
Methods A pilot study using HF10 was initiated in six patients with cutaneous or subcutaneous metastases from breast cancer. For each
patient, .5 mL of HF10 suspension containing various viral doses was injected into one nodule; .5 mL of sterile saline was
injected into another. All patients were monitored for local and systemic adverse effects. Nodules were excised 14 days after
injection for histopathologic studies.
Results All patients tolerated the intratumoral injection of HF10. No adverse effects occurred, and histopathological evaluation revealed
30% to 100% cancer cell death.
Conclusions This pilot study found HF10 to be safe and effective against metastatic breast cancer. 相似文献
17.
BACKGROUND: Oncolytic cancer therapy using herpes simplex viruses (HSV) that have direct tumoricidal effects and cancer immunotherapy using the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) have each been effective in preclinical testing. NV1034 is a multimutated oncolytic HSV carrying the gene for murine GM-CSF that attempts to combine these 2 anticancer strategies. The purpose of this study was to compare NV1034 to NV1023, the parent HSV mutants lacking GM-CSF, to determine if such combined oncolytic and immunotherapy using a single vector has advantages over oncolytic therapy alone. METHODS: Expression GM-CSF in vitro did not alter the infectivity, cytotoxicity, or replication of NV1034 compared to the noncytokine-secreting control. Tumors infected with NV1034 produced GM-CSF in picogram quantities. In vivo efficacy of the viruses against murine colorectal carcinoma CT26 and murine hepatoma Hepa l-6 was then tested in subcutaneous tumors in syngeneic Balb/c and C57 L/J mice, respectively. In these immune-competent models, NV1034 and NV1023 each demonstrated potent antitumor activity. RESULTS: Treatment with NV1034 had significantly better antitumor effect compared to treatment with NV1023. Furthermore, there was no difference in the antitumor efficacy of these viruses in mice depleted of CD4+ and CD8+ T lymphocytes. CONCLUSIONS: Viral vectors combining oncolytic and immunotherapy are promising agents in treatment of colorectal carcinoma and hepatoma. 相似文献
18.
《International journal of urology》2017,24(5):342-351
Oncolytic virus therapy has recently been recognized as a promising new option for cancer treatment. Oncolytic viruses replicate selectively in cancer cells, thus killing them without harming normal cells. Notably, T‐VEC (talimogene laherparepvec, formerly called OncoVEXGM‐CSF), an oncolytic herpes simplex virus type 1, was approved by the US Food and Drug Administration for the treatment of inoperable melanoma in October 2015, and was subsequently approved in Europe and Australia in 2016. The efficacies of many types of oncolytic viruses against urological cancers have been investigated in preclinical studies during the past decade, and some have already been tested in clinical trials. For example, a phase I trial of the third‐generation oncolytic Herpes simplex virus type 1, G47Δ, in patients with prostate cancer was completed in 2016. We summarize the current status of clinical trials of oncolytic virus therapy in patients with the three major urological cancers: prostate, bladder and renal cell cancers. In addition to Herpes simplex virus type 1, adenoviruses, reoviruses, vaccinia virus, Sendai virus and Newcastle disease virus have also been used as parental viruses in these trials. We believe that oncolytic virus therapy is likely to become an important and major treatment option for urological cancers in the near future. 相似文献
19.
BACKGROUND: The oncolytic herpes simplex-1 virus, NV1066, is a replication-competent virus that has been engineered to infect and lyse tumor cells selectively and to carry a transgene for enhanced green fluorescent protein (EGFP). The purpose of this study was to determine viral cytotoxicity in an esophageal cancer cell line and to determine whether EGFP expression could be used as a marker of viral infection. METHODS: BE3 esophageal adenocarcinoma cells were infected with NV1066 in vitro to determine cell kill and viral replication. EGFP expression was assessed by flow cytometry. The in vivo anti-tumor activity of NV1066 was tested in subcutaneous and intraperitoneal xenograft models. EGFP expression was localized in vivo by fluorescent microscopy and fluorescent laparoscopy. RESULTS: NV1066 effectively replicated within and killed BE3 cells in vitro and in vivo. EGFP expression identified infected tumor cells. After NV1066 treatment in vivo, EGFP expression localized to the tumor. In an intraperitoneal tumor model, EGFP could be visualized endoscopically using a laparoscope with a fluorescent filter. CONCLUSIONS: NV1066 has oncolytic activity against the BE3 cell line and may be a useful therapy against esophageal cancer. EGFP expression localizes the virus and may help to identify tumor deposits in vivo. Oncolytic activity with NV1066 against gastrointestinal cancers may potentially be tracked by endoscopy. 相似文献
20.
One unique feature of tumors is the presence of hypoxic regions, which occur predominantly at the tumor center. Hypoxia has
a major impact on various aspects of tumor cell function and proliferation. Hypoxic tumor cells are relatively insensitive
to conventional therapy owing to cellular adaptations effected by the hypoxic microenvironment. Recent efforts have aimed
to alter the hypoxic state and to reverse these adaptations to improve treatment outcome. One way to increase tumor oxygen
tensions is by hyperbaric oxygen (HBO) therapy. HBO therapy can influence the tumor microenvironment at several levels. It
can alter tumor hypoxia, a potent stimulus that drives angiogenesis. Hyperoxia as a result of HBO also produces reactive oxygen
species, which can damage tumors by inducing excessive oxidative stress. This review outlines the importance of oxygen to
tumors and the mechanisms by which tumors survive under hypoxic conditions. It also presents data from both experimental and
clinical studies for the effect of HBO on malignancy. 相似文献